YOLFTbeta
LTR Pharma Ltd

LTR Pharma Ltd

LTP · AU · Healthcare / Biotechnology

0.45AUD+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close0.45
Open0.44
Day Range0.435 – 0.46
52-Week Range0.35 – 0.75
Volume44.92K
Market Cap85.67M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.08
Dividend Yield0.00%
Beta2.18
50-Day Avg0.4769
200-Day Avg0.485

About

LTR Pharma Limited, a clinical-stage pharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia. Its lead product candidate is SPONTAN, an intranasal delivery technology, an oral PDE5 inhibitor and vardenafil HCL for the treatment of ED. The company was incorporated in 2020 and is headquartered in Brisbane, Australia.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Lee Rodne
  • Employees0
  • Headquarters29/97 Creek Street, Brisbane, QLD, Australia, 4000, Australia
  • Websitehttps://ltrpharma.com

Leadership

  • Mr. Lee RodneExecutive Chairman
  • Mr. Jacques SchipperChief Financial Officer
  • Mr. Peter McLennanChief Operating Officer
  • Prof. Geoffrey A. StrangeChief Medical Officer
  • Mr. Danny ZanardoChief Commercial Officer
  • Mr. Euh Hwang B.A., L.L.B.Joint Company Secretary · b. 1986
  • Ms. Elizabeth SpoonerJoint Company Secretary

Financials

Income Statement

Currency: AUD2021-06-302022-06-302023-06-302024-06-302025-06-30
Total Revenue-9.32K9049.33K2.10M
Growth (%)---99.03%+54711.11%+4164.38%
Gross Profit----145.78K
Gross Margin----6.93%
Operating Expense----5.33M
Operating Income-28.57K-1.01M-1.41M-6.41M-5.18M
Operating Margin--10880.15%-1565711.11%-12990.11%-246.30%
EBITDA--1.03M-1.45M-6.95M-5.59M
EBITDA Margin--11020.32%-1616538.89%-14097.03%-265.79%
Net Income-40.80K-1.03M-1.45M-6.95M-5.59M
Net Income Margin--11020.60%-1616566.67%-14097.89%-265.90%
R&D-348.31K817.84K3.51M2.79M
R&D as % of Total Revenue-3737.18%908705.56%7106.78%132.48%
Interest Expense9.38K272042223
Interest Expense % of Total Revenue-0.29%22.22%0.86%0.00%

Balance Sheet

Currency: AUD2021-06-302022-06-302023-06-302024-06-302025-06-30
Total Assets422.70K2.25M2.09M3.37M32.21M
Total Liabilities463.50K475.91K21.26K428.54K700.57K
Total Equity-40.80K1.77M2.07M2.94M31.51M
Cash146.14K1.91M1.73M3.10M31.81M
Net Debt213.36K----

Cash Flow

Currency: AUD2021-06-302022-06-302023-06-302024-06-302025-06-30
Operating Cash Flow--568.18K-1.54M-5.09M-
Investing Cash Flow---1.99K-1.98K-
Financing Cash Flow178.34K2.34M1.38M6.50M33.37M
Capital Expenditure001.99K1.98K13.17K
Free Cash Flow-29.07K-568.18K-1.54M-5.09M-4.45M
FCF to OCF-100.00%100.13%100.04%-

Earnings

Report DateFeb 26, 2025Aug 28, 2025
EPS Estimate0.000.00
EPS Actual-0.02-0.02
Surprise--
Timing--

Key Statistics & Ratios

Market Cap85.67M
Enterprise Value60.54M
Trailing P/E0.00
Forward P/E0.00
Price / Sales118.34
Price / Book3.96
EPS-0.08
Book Value0.111
Revenue (TTM)723.93K
Gross Profit (TTM)-5.97M
EBITDA-13.99M
Profit Margin0.00%
Operating Margin-1218.41%
Return on Equity-54.73%
Return on Assets-32.96%
Shares Outstanding182.27M
Shares Float106.62M
Beta2.18
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%